MARKET

RUBY

RUBY

Rubius Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

25.06
-0.07
-0.28%
Pre Market: 24.05 -1.01 -4.03% 08:00 05/07 EDT
OPEN
25.00
PREV CLOSE
25.13
HIGH
25.36
LOW
23.82
VOLUME
2
TURNOVER
--
52 WEEK HIGH
38.71
52 WEEK LOW
4.200
MARKET CAP
2.20B
P/E (TTM)
-12.0434
1D
5D
1M
3M
1Y
5Y
Immuno-oncology Therapy Market Size, Share, Growth,Trends, COVID-19 Analysis and Forecast 2021-2028
pune, India, Thu, 06 May 2021 23:32:16 / Comserve Inc. / -- The global Immuno-oncology Therapy market size is projected to reach US$ 1648.7 million by 2028,...
Comserve · 9h ago
Cell Therapy and Tissue Engineering Market Trend 2021, Size, Industry Growth by Global Major Companies Profile, Competitive Landscape and Key Regions 2026
May 06, 2021 (The Expresswire) -- Global "Cell Therapy and Tissue Engineering Market" (2021-2026) examines the effect of different Factors affecting the...
The Express Wire · 1d ago
Cell Therapy and Tissue Engineering Market 2021 Explosive Factors of Revenue by Industry Demography, Demand, Organization Size, Technological Advancement, Growing Prominence Analysis, Share and Forecast to 2025
May 06, 2021 (The Expresswire) -- Final Report will add the analysis of the impact of COVID-19 on this industry. Global “Cell Therapy and Tissue Engineering...
The Express Wire · 1d ago
Rubius Therapeutics (RUBY) Gets a Hold Rating from Morgan Stanley
In a report released today, Matthew Harrison from Morgan Stanley maintained a Hold rating on Rubius Therapeutics (RUBY), with a price target of $24.00.
SmarterAnalyst · 04/19 16:29
DJ Rubius Therapeutics Price Target Raised to $24.00/Share From $10.00 by Morgan Stanley
Dow Jones · 04/19 15:19
DJ Rubius Therapeutics Is Maintained at Equal-Weight by Morgan Stanley
Dow Jones · 04/19 15:19
Morgan Stanley Maintains Equal-Weight on Rubius Therapeutics, Raises Price Target to $24
Morgan Stanley maintains Rubius Therapeutics (NASDAQ:RUBY) with a Equal-Weight and raises the price target from $10 to $24.
Benzinga · 04/19 15:09
DJ 'Natural Killer Cells' and Other Promising Cancer Treatments -- Barrons.com
Dow Jones · 04/15 16:29
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RUBY. Analyze the recent business situations of Rubius Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RUBY stock price target is 30.20 with a high estimate of 40.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 130
Institutional Holdings: 78.57M
% Owned: 89.33%
Shares Outstanding: 87.95M
TypeInstitutionsShares
Increased
26
2.20M
New
12
223.20K
Decreased
33
585.07K
Sold Out
8
138.22K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.09%
Pharmaceuticals & Medical Research
-0.29%
Key Executives
Chairman/Director
David Epstein
President/Chief Executive Officer/Director
Pablo Cagnoni
Chief Financial Officer
Jose Carmona
Chief Scientific Officer
Laurence Turka
Other
Christina Coughlin
Secretary
Maiken Keson-Brookes
Other
Greg ..
Independent Director
Noubar Afeyan
Independent Director
Francis Cuss
Independent Director
Natalie Holles
Independent Director
Anne Prener
Independent Director
Michael Rosenblatt
Independent Director
Catherine Sohn
Independent Director
Jonathan Symonds
No Data
About RUBY
Rubius Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing medicines called Red Cell Therapeutics (RCTs). Its RED PLATFORM is designed to genetically engineer, and culture Red Cell Therapeutics that are ready-to-use cellular therapies for the treatment of cancer and autoimmune diseases. It develops RCT product candidates based on therapeutic modalities such as immune system stimulation for the treatment of cancer and immune modulation to induce tolerance in autoimmune diseases. Its oncology program, RTX-240, is in the Phase I/II clinical trial for relapsed/refractory or solid tumors and in the Phase I clinical trial for relapsed/refractory acute myeloid leukemia (AML). Its artificial antigen presenting cell (aAPC) program, RTX-321, is in the Phase I clinical trial for the treatment of advanced human papillomavirus (HPV) 16-positive cancers.

Webull offers kinds of Rubius Therapeutics Inc stock information, including NASDAQ:RUBY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RUBY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RUBY stock methods without spending real money on the virtual paper trading platform.